Engrail Therapeutics

Engrail Therapeutics is a clinical-stage precision-neuroscience pharmaceutical company founded in 2019 and headquartered in San Diego, California. It applies precision chemistry and pharmacology to scientifically validated mechanisms of action, developing targeted small-molecule therapies for neuropsychiatric and neurodevelopmental diseases with significant unmet need — including generalized anxiety disorder, major depressive disorder characterized by anhedonia, post-traumatic stress disorder and rare neurodegenerative conditions. Its lead program, ENX-102, is a highly selective GABA-A alpha-2,3,5 positive allosteric modulator in Phase 2 (the ENCALM trial) for generalized anxiety disorder; ENX-104 is in clinical development for anhedonic depression. The company closed an oversubscribed $157M Series B in March 2024 co-led by F-Prime Capital, Forbion and Norwest Venture Partners, bringing total capital raised since inception past $220M. Engrail publishes no product or developer API; the machine-readable surfaces catalogued here are the public read-only content API and the OAuth-protected Model Context Protocol servers exposed by its corporate website.

Engrail Therapeutics publishes 1 API on the APIs.io network: Site Content API. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Neuroscience.

Engrail Therapeutics’ developer surface includes engineering blog, support, authentication, and 19 more developer resources.

🌐 Visit website 📡 Source on GitHub

37.6/100 thin ▬ flat Agent 30/100 agent aware Full breakdown ↓
scored 2026-08-05 · rubric v0.9.1

2 APIs 1 MCP Servers

CompanyBiotechnologyPharmaceuticalsLife SciencesNeuroscienceClinical TrialsDrug DevelopmentHealthcareMental HealthModel Context Protocol

Kin Score

Kin Score How this is scored →
scored 2026-08-05 · rubric v0.9.1

Composite quality — 37.6/100 · thin

Contract Quality 15.7 / 25

Developer Ergonomics 3.8 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.0 / 13

Governance 2.5 / 12

Discoverability 8.7 / 10

Agent readiness — 30/100 · agent aware

Machine-Readable Contract 18 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 10 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 5 / 5

Well-Known Catalog 4 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/engrail-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

APIs 2

Individual APIs this provider publishes, each with its own machine-readable definition.

Engrail Therapeutics Site Content API

The public, anonymously-readable content API exposed by engrail.com at /wp-json/wp/v2. Sixteen read operations over posts, pages, media, categories, tags, comments, and the site...

Engrail Therapeutics MCP Servers

Two live Model Context Protocol servers registered under the `mcp` REST namespace on engrail.com, fronted by RFC 8414 and RFC 9728 OAuth discovery documents at the apex. Both ar...

MCP Servers 1

Model Context Protocol servers that expose these APIs to AI agents.

Scopes 1

OAuth scopes governing access to this provider's APIs.

Engrail Therapeutics Scopes

1 scope · authorizationCode

1 scopes

SCOPES

Resources

Agent Surfaces 3

MCP servers, agent skills, and machine-readable catalogs

WellKnown

WellKnown

LLMsTxt

LLMsTxt

AgentSkill

AgentSkill

Design & Contract 3

Pagination, idempotency, versioning, errors, and events

Conventions

Conventions

Conformance

Conformance

Lifecycle

Lifecycle

Access & Security 3

Authentication, authorization, and security posture

Authentication

Authentication

OAuthScopes

OAuthScopes

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 3

Pricing, plans, and the legal terms of use

TermsOfService

TermsOfService

PrivacyPolicy

PrivacyPolicy

LegalDisclaimer

LegalDisclaimer

Company 7

The organization behind the API

Website

About

Blog

BlogRSS

Careers

Partners

LinkedIn

Scroll for all 7

Other 2

Properties that don't map to a standard resource type

SecondaryMarket

SecondaryMarket

Pipeline

Pipeline

Source (apis.yml)

aid: engrail-therapeutics
name: Engrail Therapeutics
description: Engrail Therapeutics is a clinical-stage precision-neuroscience pharmaceutical company founded in 2019 and headquartered
  in San Diego, California. It applies precision chemistry and pharmacology to scientifically validated mechanisms of action,
  developing targeted small-molecule therapies for neuropsychiatric and neurodevelopmental diseases with significant unmet
  need — including generalized anxiety disorder, major depressive disorder characterized by anhedonia, post-traumatic stress
  disorder and rare neurodegenerative conditions. Its lead program, ENX-102, is a highly selective GABA-A alpha-2,3,5 positive
  allosteric modulator in Phase 2 (the ENCALM trial) for generalized anxiety disorder; ENX-104 is in clinical development
  for anhedonic depression. The company closed an oversubscribed $157M Series B in March 2024 co-led by F-Prime Capital, Forbion
  and Norwest Venture Partners, bringing total capital raised since inception past $220M. Engrail publishes no product or
  developer API; the machine-readable surfaces catalogued here are the public read-only content API and the OAuth-protected
  Model Context Protocol servers exposed by its corporate website.
image: https://www.engrail.com/wp-content/uploads/2022/05/logo.png
url: https://raw.githubusercontent.com/api-evangelist/engrail-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pipeline
specificationVersion: '0.20'
created: '2026-08-01'
modified: '2026-08-01'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Neuroscience
- Clinical Trials
- Drug Development
- Healthcare
- Mental Health
- Model Context Protocol
apis:
- aid: engrail-therapeutics:content
  name: Engrail Therapeutics Site Content API
  description: The public, anonymously-readable content API exposed by engrail.com at /wp-json/wp/v2. Sixteen read operations
    over posts, pages, media, categories, tags, comments, and the site's own type/taxonomy/status vocabulary, plus site search.
    Derived mechanically from the provider's own WordPress REST route-discovery document — Engrail publishes no hand-authored
    OpenAPI.
  humanURL: https://www.engrail.com/investors-media/
  baseURL: https://www.engrail.com/wp-json
  tags:
  - Content
  - Search
  - Media
  properties:
  - type: OpenAPI
    url: openapi/engrail-therapeutics-content-openapi.yml
  - type: Overlay
    url: overlays/engrail-therapeutics-content-overlay.yaml
  - type: ErrorCatalog
    url: errors/engrail-therapeutics-problem-types.yml
  - type: DataModel
    url: data-model/engrail-therapeutics-data-model.yml
  - type: Blog
    url: https://www.engrail.com/investors-media/
- aid: engrail-therapeutics:mcp
  name: Engrail Therapeutics MCP Servers
  description: Two live Model Context Protocol servers registered under the `mcp` REST namespace on engrail.com, fronted by
    RFC 8414 and RFC 9728 OAuth discovery documents at the apex. Both are OAuth-protected — anonymous tools/list returns HTTP
    401 — so the live tool manifest is not readable and no tool list is recorded.
  humanURL: https://www.engrail.com/
  baseURL: https://www.engrail.com/wp-json/mcp/mcp-oauth-server
  tags:
  - Model Context Protocol
  - Agents
  properties:
  - type: MCPServer
    url: mcp/engrail-therapeutics-mcp.yml
  - type: ToolCrosswalk
    url: mcp/engrail-therapeutics-tool-crosswalk.yml
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.engrail.com/
- type: SecondaryMarket
  url: https://forgeglobal.com/engrail-therapeutics_stock/
- type: About
  url: https://www.engrail.com/about-us/
- type: Blog
  url: https://www.engrail.com/investors-media/
- type: BlogRSS
  url: https://www.engrail.com/feed/
- type: Support
  url: https://www.engrail.com/contact-us/
- type: TermsOfService
  url: https://www.engrail.com/terms-of-use/
- type: PrivacyPolicy
  url: https://www.engrail.com/privacy-policy/
- type: LegalDisclaimer
  url: https://www.engrail.com/legal-disclaimer/
- type: Careers
  url: https://www.engrail.com/careers/
- type: Partners
  url: https://www.engrail.com/partners/
- type: Pipeline
  url: https://www.engrail.com/pipeline/
- type: LinkedIn
  url: https://www.linkedin.com/company/engrail-therapeutics
- type: WellKnown
  url: well-known/engrail-therapeutics-well-known.yml
- type: Authentication
  url: authentication/engrail-therapeutics-authentication.yml
- type: OAuthScopes
  url: scopes/engrail-therapeutics-scopes.yml
- type: Conventions
  url: conventions/engrail-therapeutics-conventions.yml
- type: Conformance
  url: conformance/engrail-therapeutics-conformance.yml
- type: Lifecycle
  url: lifecycle/engrail-therapeutics-lifecycle.yml
- type: DomainSecurity
  url: security/engrail-therapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/engrail-therapeutics-llms.txt
- type: AgentSkill
  url: skills/_index.yml
x-enrichment:
  date: '2026-08-01'
  status: enriched
  artifacts_added: 20
  pass: local-v1